 Molecular Partners AG NASDAQ: MOLN announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza ESWI Conference. The single-arm Phase 2a study enrolled 12 patients with mild to moderate COVID-19 symptoms. 